Risk factors of pneumonitis following chemoradiotherapy for lung cancer.

The purpose of this retrospective study was to identify risk factors associated with development of pneumonitis following chemoradiotherapy (CRT). We examined 60 patients (pts) who received CRT from May 1993 to August 1995. Factors evaluated included total radiation dose, field-size, irradiated site, type of chemotherapy, pulmonary fibrosis and treatment schedule (concurrent versus sequential). There were 17 pts (28.3%) who had > or = Grade 2 pulmonary toxicity. There was no significant relationship between total radiation dose, field-size > or = 200 cm2, pulmonary fibrosis or treatment schedule and risk of pneumonitis. In the sequential treatment group (22 pts), no relationship was noted between any factor and the risk of pneumonitis, while in the concurrent treatment group (38 pts), the incidence of pneumonitis was more frequent (53.8%) in patients with field-size > or = 200 cm2 than in patients with field-size < 200 cm2 (P < 0.05). In those who received concurrent treatment, including weekly CPT-11, pneumonitis was more frequent (56.3%) than in those without CPT-11 (13.6%, P < 0.01). When the lower lung field was included in the radiation site, the incidence of pneumonitis was 70% compared with 20% for other sites (P < 0.01). Multivariate analysis revealed a significant relationship between radiation site and the risk of pneumonitis (P = 0.0096). CPT-11 was significant (P = 0.038) only in the concurrent group. Pneumonitis was reversible in all but one pt by steroid therapy. Thus, irradiated site (included lower lung field) and concurrent CRT used with weekly CPT-11 were treatment factors significantly associated with a higher risk of pneumonitis following CRT.

[1]  J. Zaunders,et al.  Radiation Pneumonitis: A Possible Lymphocyte-mediated Hypersensitivity Reaction , 1993, Annals of Internal Medicine.

[2]  D. Boothman,et al.  Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. , 1992, International journal of radiation oncology, biology, physics.

[3]  Y. Nishiwaki,et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R K Ten Haken,et al.  Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. , 1994, International journal of radiation oncology, biology, physics.

[5]  D. Gandara,et al.  Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Mitsuhashi,et al.  Radiation therapy for Stage I-III epidermoid carcinoma of the lung , 1992 .

[7]  C. Hennequin,et al.  Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. , 1994, Cancer research.

[8]  M. Fukuoka,et al.  Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts , 1997, Japanese journal of cancer research : Gann.

[9]  M. Fukuoka,et al.  CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Gross.  Pulmonary effects of radiation therapy. , 1977, Annals of internal medicine.

[11]  Hector Battifora,et al.  Radiation oncology: rationale, technique, results , 1973 .

[12]  S Kramer,et al.  A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non‐oat‐cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group , 1980, Cancer.

[13]  S. Anthony,et al.  Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer , 1996, Annals of Internal Medicine.

[14]  P. Gibson,et al.  Radiation-induced lung injury: a hypersensitivity pneumonitis? , 1988, Annals of internal medicine.

[15]  M. Fukuoka,et al.  [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group]. , 1991, Gan to kagaku ryoho. Cancer & chemotherapy.

[16]  D. Sugarbaker,et al.  Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. John,et al.  Chemoradiation : an integrated approach to cancer treatment , 1993 .

[18]  P. Warde,et al.  Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Eisenhauer,et al.  Current perspectives on camptothecins in cancer treatment. , 1996, British Journal of Cancer.

[20]  A. Turrisi,et al.  The evolving role of radiation therapy in the treatment of locally advanced lung cancer. , 1993, Seminars in oncology.

[21]  R. Comis,et al.  The pulmonary toxicity of antineoplastic agents. , 1982, Seminars in oncology.

[22]  M. Fukuoka,et al.  Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. , 1991, Journal of the National Cancer Institute.

[23]  S. Breit,et al.  Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. , 1995, International journal of radiation oncology, biology, physics.